Research specialized in the field of hematology oncology over relatively
recent years has revolutionized patient care and led to an array of chemotherapeutic
agents approved by the Food and Drug Administration. Both oral and intravenous drug
formulations have been marketed, including targeted therapies, for several hematologic
disorders including acute and chronic leukemias, Hodgkin and non-Hodgkin’s
lymphomas, multiple myeloma, and myelofibrosis. The primary focus of this chapter
will include latest chemotherapy developments in hematology covering critical topics
of pharmacology, pharmacokinetics/pharmacodynamics, and pivotal clinical studies
addressing both labeled and off-labeled indications. Lastly, future directions will be
addressed, where applicable, in this continuously evolving clinical field.
Keywords: Acute lymphoblastic leukemia, Anaplastic large cell lymphoma, Bone
marrow transplant, Cancer, Chemotherapy, Chronic lymphocytic leukemia,
Chronic myeloid leukemia, Hematology, Hodgkin lymphoma, Mantle cell
lymphoma, Multiple myeloma, Myelofibrosis, Non-Hodgkin’s lymphoma,
Oncology, T-cell lymphoma.
